Cargando…

Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma

BACKGROUND: Papillary renal cell carcinoma (PRCC) is the second most common adult kidney cancer histology, constituting 15-20% of cases. While some patients may have indolent PRCC tumors that grow slowly, other tumors rapidly metastasize. Some PRCC tumors respond to immune checkpoint inhibitors. Thu...

Descripción completa

Detalles Bibliográficos
Autores principales: Haake, Scott, Brewer, Jared, Nesta, Alex, Vento, Joseph, Beckermann, Kathryn, Reddy, Anupama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445564/
http://dx.doi.org/10.1093/oncolo/oyad216.005
_version_ 1785094197837037568
author Haake, Scott
Brewer, Jared
Nesta, Alex
Vento, Joseph
Beckermann, Kathryn
Reddy, Anupama
author_facet Haake, Scott
Brewer, Jared
Nesta, Alex
Vento, Joseph
Beckermann, Kathryn
Reddy, Anupama
author_sort Haake, Scott
collection PubMed
description BACKGROUND: Papillary renal cell carcinoma (PRCC) is the second most common adult kidney cancer histology, constituting 15-20% of cases. While some patients may have indolent PRCC tumors that grow slowly, other tumors rapidly metastasize. Some PRCC tumors respond to immune checkpoint inhibitors. Thus, understanding the immune tumor microenvironment and how it correlates with patient outcomes in this relatively rare disease is a critical need. Spatial interrogation of patient samples has the potential to offer novel insights into the tumor-immune axis and provide avenues for enhanced diagnosis and treatment. Addressing questions of spatial arrangement within tumors has remained a technical and biological challenge, but emerging spatial biology technologies provide molecular data at single cell resolution. We hypothesized that the spatial interaction of immune, stromal and tumor cells would be prognostic for PRCC patients. METHODS: A tissue microarray was assembled from an archive of ~100 patients presenting with PRCC. This dataset was assayed with PhenoCycler/CODEX (Akoya Biosciences) using a 31-antibody panel with immune- and cancer-related proteins. We have developed methodology and novel algorithms to perform signal normalization, cell segmentation, and cell typing. We computed neighborhoods for each of 2.5 million cells and performed network analysis to identify spatial clusters. This method allowed us to identify clusters consistently present across multiple TMA spots from the same patient and across multiple patients. RESULTS: Using spatial neighborhood analysis, we have identified diverse spatial clusters of potential clinical relevance, including five distinct M2 macrophage spatial clusters. We have described one of the clusters as being physically associated with helper T cells, which is visualized on a PRCC spot and shows co-occurence of M2-macrophages (CD163) and helper T cells (CD4). This pattern was replicated in additional TMA spots from the same patient. In contrast, other clusters of M2-macrophages (M2-M2 spatial cluster and M2-M1 macrophages) are visualized to show vastly different cellular neighborhoods. Clinical associations show that the patients with presence of the M2-T helper cluster have a poor cancer-associated survival (p=0.005). In comparison, the total proportion of M2 macrophages is not associated with survival (p=0.4), highlighting the importance of characterizing spatial interactions beyond cell type quantitation. [Image: see text] CONCLUSIONS: In summary, we highlight the utility of spatial biology to explain the heterogeneity in patients’ tumors and to uncover novel correlates of clinical phenotypes, establishing a platform for future discovery in this field and the identification of additional spatial correlates of patient outcome and clinical response. CDMRP DOD Funding: yes
format Online
Article
Text
id pubmed-10445564
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104455642023-08-24 Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma Haake, Scott Brewer, Jared Nesta, Alex Vento, Joseph Beckermann, Kathryn Reddy, Anupama Oncologist Oral Abstract Presentations BACKGROUND: Papillary renal cell carcinoma (PRCC) is the second most common adult kidney cancer histology, constituting 15-20% of cases. While some patients may have indolent PRCC tumors that grow slowly, other tumors rapidly metastasize. Some PRCC tumors respond to immune checkpoint inhibitors. Thus, understanding the immune tumor microenvironment and how it correlates with patient outcomes in this relatively rare disease is a critical need. Spatial interrogation of patient samples has the potential to offer novel insights into the tumor-immune axis and provide avenues for enhanced diagnosis and treatment. Addressing questions of spatial arrangement within tumors has remained a technical and biological challenge, but emerging spatial biology technologies provide molecular data at single cell resolution. We hypothesized that the spatial interaction of immune, stromal and tumor cells would be prognostic for PRCC patients. METHODS: A tissue microarray was assembled from an archive of ~100 patients presenting with PRCC. This dataset was assayed with PhenoCycler/CODEX (Akoya Biosciences) using a 31-antibody panel with immune- and cancer-related proteins. We have developed methodology and novel algorithms to perform signal normalization, cell segmentation, and cell typing. We computed neighborhoods for each of 2.5 million cells and performed network analysis to identify spatial clusters. This method allowed us to identify clusters consistently present across multiple TMA spots from the same patient and across multiple patients. RESULTS: Using spatial neighborhood analysis, we have identified diverse spatial clusters of potential clinical relevance, including five distinct M2 macrophage spatial clusters. We have described one of the clusters as being physically associated with helper T cells, which is visualized on a PRCC spot and shows co-occurence of M2-macrophages (CD163) and helper T cells (CD4). This pattern was replicated in additional TMA spots from the same patient. In contrast, other clusters of M2-macrophages (M2-M2 spatial cluster and M2-M1 macrophages) are visualized to show vastly different cellular neighborhoods. Clinical associations show that the patients with presence of the M2-T helper cluster have a poor cancer-associated survival (p=0.005). In comparison, the total proportion of M2 macrophages is not associated with survival (p=0.4), highlighting the importance of characterizing spatial interactions beyond cell type quantitation. [Image: see text] CONCLUSIONS: In summary, we highlight the utility of spatial biology to explain the heterogeneity in patients’ tumors and to uncover novel correlates of clinical phenotypes, establishing a platform for future discovery in this field and the identification of additional spatial correlates of patient outcome and clinical response. CDMRP DOD Funding: yes Oxford University Press 2023-08-23 /pmc/articles/PMC10445564/ http://dx.doi.org/10.1093/oncolo/oyad216.005 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Oral Abstract Presentations
Haake, Scott
Brewer, Jared
Nesta, Alex
Vento, Joseph
Beckermann, Kathryn
Reddy, Anupama
Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma
title Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma
title_full Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma
title_fullStr Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma
title_full_unstemmed Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma
title_short Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma
title_sort spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma
topic Oral Abstract Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445564/
http://dx.doi.org/10.1093/oncolo/oyad216.005
work_keys_str_mv AT haakescott spatialproteomicsenablesidentificationofprognosticbiomarkersinpapillaryrenalcellcarcinoma
AT brewerjared spatialproteomicsenablesidentificationofprognosticbiomarkersinpapillaryrenalcellcarcinoma
AT nestaalex spatialproteomicsenablesidentificationofprognosticbiomarkersinpapillaryrenalcellcarcinoma
AT ventojoseph spatialproteomicsenablesidentificationofprognosticbiomarkersinpapillaryrenalcellcarcinoma
AT beckermannkathryn spatialproteomicsenablesidentificationofprognosticbiomarkersinpapillaryrenalcellcarcinoma
AT reddyanupama spatialproteomicsenablesidentificationofprognosticbiomarkersinpapillaryrenalcellcarcinoma